達(dá)妥木單抗?，Daratumumab，CAS:945721-28-8， AntibodySystem Laboratories

貨號：DHD80801

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75142.html

別名：HuMax-CD38, CAS: 945721-28-8

簡介：

達(dá)雷木單抗?Daratumumab (Anti-Human CD38) 是首創(chuàng)的特異性抗 CD38 單克隆抗體 (IgG1)。Daratumumab 具有抗多發(fā)性骨髓瘤(MM) 的作用。Daratumumab 損傷了 MM 細(xì)胞的粘附，從而增加了 MM 對蛋白酶體抑制的敏感性。

貨號：DHD80801

產(chǎn)品品牌：Antibodysystem

通用名：Daratumumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：HuMax-CD38

靶點;物種：Human CD38

種類：Homo sapiens

受體鑒定：IgG1-kappa

CAS: 945721-28-8

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. PMID: 34192431
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. PMID: 27557302
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. PMID: 31141632
Daratumumab for the treatment of multiple myeloma. PMID: 28434255
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. PMID: 27705267
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. PMID: 32682484
Daratumumab in AL amyloidosis. PMID: 35507692
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. PMID: 34655533
Daratumumab in multiple myeloma. PMID: 30951198
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. PMID: 34087126
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. PMID: 29231133
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. PMID: 31936617
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis. PMID: 35416593
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. PMID: 33806310
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931
Daratumumab: A review of current indications and future directions. PMID: 35184871
Daratumumab: Beyond Multiple Myeloma. PMID: 34312046
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. PMID: 30828799
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. PMID: 28637662
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. PMID: 35903924
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. PMID: 35580269
Daratumumab for immune thrombotic thrombocytopenic purpura. PMID: 34551063
Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. PMID: 33387628
Daratumumab for treatment-refractory antibody-mediated diseases in neurology. PMID: 35098616
Daratumumab subcutaneous formulation for the treatment of multiple myeloma. PMID: 32750265
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. PMID: 26308596
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. PMID: 32213342
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. PMID: 35462406
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. PMID: 27222480
Daratumumab: First Global Approval. PMID: 26729183
Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. PMID: 33685975
Daratumumab for the treatment of AL amyloidosis. PMID: 30033840
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. PMID: 34963325
Daratumumab: Therapeutic asset, biological trap! PMID: 29336950
[Daratumumab for multiple myeloma]. PMID: 30430991
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. PMID: 32970151
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. PMID: 32936436
Daratumumab for the Treatment of Multiple Myeloma. PMID: 29915586
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2?MM-014 trial. PMID: 35133221
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. PMID: 33606004
Daratumumab: monoclonal antibody therapy to treat multiple myeloma. PMID: 27910963
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. PMID: 33216361
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. PMID: 21187443
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. PMID: 32659139
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. PMID: 32470437
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. PMID: 29127588
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma. PMID: 30830601
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. PMID: 30237264
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. PMID: 27307294
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. PMID: 30136602
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. PMID: 33289427
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. PMID: 27806428
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. PMID: 27363983
Evolving Role of Daratumumab: From Backbencher to Frontline Agent. PMID: 32331971
The safety of daratumumab for the treatment of multiple myeloma. PMID: 28490215
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. PMID: 34879994
[Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories]. PMID: 28185460
Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature. PMID: 33067143
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. PMID: 35151867
Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy. PMID: 35190038
Retrospective review of accelerated daratumumab administration. PMID: 33866892
Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature. PMID: 33245179
Single-agent daratumumab for refractory POEMS syndrome. PMID: 35253931